verapamil has been researched along with Kidney Diseases in 43 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Only angiotensin-converting enzyme inhibitor (trandolapril) treatment, alone or better combined with verapamil, reduces proteinuria and increases serum albumin." | 5.10 | Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial. ( , 2002) |
| "Non-dihydropyridine calcium antagonists such as verapamil are equally effective in reducing proteinuria as ACE inhibitors in hypertensive patients with diabetic nephropathy." | 5.09 | Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease. ( de Jong, PE; de Zeeuw, D; Hemmelder, MH, 1999) |
| "Cyclosporine A (CsA) nephrotoxicity has been suggested to be aggravated in the presence of ischemia, as occurs after renal transplantation." | 3.69 | Deleterious effect of cyclosporins on the ischemic kidney in the rat and the protection by the calcium antagonist verapamil. ( Ar'Rajab, A; Dawidson, IJ; Harris, RB; Mileski, WJ; Sentementes, JT, 1994) |
| "Cephaloridine produces proximal tubular necrosis in the rabbit kidney." | 3.68 | Effect of verapamil on cephaloridine nephrotoxicity in the rabbit. ( Browning, MC, 1990) |
| "Verapamil treatment was also associated with a decrease in CsA dose requirement (7." | 2.68 | A randomized controlled trial of verapamil on cyclosporine nephrotoxicity in heart and lung transplant recipients. ( Cardella, C; Cattran, D; Chan, C; Maurer, J; Pei, Y, 1997) |
| "To determine whether verapamil, diltiazem, or nifedipine affect digitoxin kinetics, glycoside plasma concentrations and renal excretion were measured before and during steady-state dosing in 30 patients with cardiac insufficiency." | 2.66 | Effects of verapamil, diltiazem, and nifedipine on plasma levels and renal excretion of digitoxin. ( Kuhlmann, J, 1985) |
| "Verapamil therapy was also associated with significantly fewer rejection episodes (3 of 22; 14%) within 4 weeks of transplantation than CsA therapy alone (10 of 18; 56%)." | 2.38 | Improvement of cadaver renal transplantation outcomes with verapamil: a review. ( Dawidson, I; Rooth, P, 1991) |
| " We conducted virtual drug-drug interactions studies between DABE and the P-glycoprotein inhibitor verapamil in RI populations using physiologically based pharmacokinetic modeling." | 1.51 | Assessing Potential Drug-Drug Interactions Between Dabigatran Etexilate and a P-Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling. ( Doki, K; Homma, M; Neuhoff, S; Rostami-Hodjegan, A, 2019) |
| "Treatment with verapamil induced a dose-dependent potentiation in the biochemical parameters of nephrotoxicity that was significant only at the highest dose used (7 mg/kg)." | 1.31 | The effect of calcium load and the calcium channel blocker verapamil on gentamicin nephrotoxicity in rats. ( Al-Qarawi, AA; Ali, BH; Mousa, HM, 2002) |
| " The aim of this study was to determine whether these inhibitors can prevent the toxic effects of Cd on the kidney which is the critical organ." | 1.30 | Effect of calmodulin-inhibitors and verapamil on the nephrotoxicity of cadmium in rat. ( Bernard, A; Lermioglu, F, 1998) |
| "Nifedipine and verapamil have been shown previously to protect against renal function alterations induced by shock wave lithotripsy (SWL) in humans and rats; however, the mechanism is unclear." | 1.30 | Nifedipine, verapamil and diltiazem block shock-wave-induced rises in cytosolic calcium in MDCK cells. ( Chen, WC; Jan, CR; Tseng, CJ; Wu, SN, 1998) |
| "Verapamil was given as a sustained release preparation of 180 mg twice daily starting 2 days before the aminoglycoside, and continued for 4 days post-gentamicin therapy." | 1.29 | The effect of verapamil on the nephrotoxic potential of gentamicin as measured by urinary enzyme excretion in healthy volunteers. ( Goldfarb, AL; Kazierad, DJ; Nix, DE; Schentag, JJ; Wojcik, GJ, 1995) |
| "In a second group (n = 9), hypoxemia induced marked significant decreases in GFR, RBF and urine flow rate (-22 +/- 5%, -18 +/- 6% and -34 +/- 7% respectively)." | 1.29 | Protection from hypoxemic renal dysfunction by verapamil and manganese in the rabbit. ( Guignard, JP; Heumann, C; Semama, D, 1995) |
| " If such an effect occurs in vivo, the ATP deficit will affect calcium extrusion pumps, so triggering vasoconstriction which is the major side effect of Cyclosporine A." | 1.28 | The restoration of ATP synthesis may explain the protective effect of calcium antagonists against cyclosporine A nephrotoxicity. ( Berland, Y; Chauvet-Monges, AM; Crevat, A; Dussol, B; Elsen, R; Salducci, MD, 1992) |
| "In verapamil-treated rats (5 mg/kg/day), no histological or biochemical evidence of renal injury was detected." | 1.28 | Verapamil increases the nephrotoxic potential of gentamicin in rats. ( Fadali, GA; Farag, MM; Kandil, M, 1992) |
| "Verapamil was given in the drinking water for 7 days." | 1.28 | Effect of ciclosporin on cardiac output and regional blood flow in rats: ciclosporin-induced nephropathy and its prevention with calcium channel blocker. ( Kim, T; Kishimoto, T; Maekawa, M; Maekawa, T; Nakatani, T; Ohyama, A; Sakamoto, W; Tsujino, T; Yoshimura, R, 1992) |
| "Verapamil was given in the drinking water and the average dose calculated from the amount of drinking was 4." | 1.28 | [Effects of verapamil on cyclosporine. A (CsA)-induced nephropathy in ischemic kidney model in rats: changes in systemic hemodynamics and hepatic and renal microsomal cytochrome P-450]. ( Kawashima, H; Kim, T; Kishimoto, T; Kusunose, E; Maekawa, T; Nakatani, T; Ohyama, A; Sakamoto, W; Tsujino, T; Yoshimura, R, 1991) |
| " A direct toxic effect of CsA on renal tubule epithelia was demonstrated using nigrosine uptake and LDH release as indicators of cell death." | 1.28 | Mechanisms of cyclosporine A toxicity in defined cultures of renal tubule epithelia: a role for cysteine proteases. ( Hartz, PA; Wilson, PD, 1991) |
| "Nephrotoxicity is the most troublesome side effect of cyclosporin A (CSA) therapy." | 1.28 | Lack of effect of verapamil and MDL 646, a cytoprotective PGE1 analogue on cyclosporin A nephrotoxicity in vitro. ( Hall, TJ; Heckel, C, 1990) |
| "Both developed colic like complaints related to the urogenital system, which disappeared after disruption of treatment and reoccured after restarting." | 1.26 | [Partusisten as a possible cause for renal colics (author's transl)]. ( Fritzsche, R; Schmidt, EH; Wagner, H, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (13.95) | 18.7374 |
| 1990's | 26 (60.47) | 18.2507 |
| 2000's | 4 (9.30) | 29.6817 |
| 2010's | 7 (16.28) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avdeef, A | 1 |
| Tam, KY | 1 |
| Hammoud, SH | 1 |
| Alkhansa, S | 1 |
| Mahjoub, N | 1 |
| Omar, AG | 1 |
| El-Mas, MM | 1 |
| Eid, AA | 1 |
| Hafez, HM | 1 |
| Ibrahim, MA | 1 |
| Zedan, MZ | 1 |
| Hassan, M | 1 |
| Hassanein, H | 1 |
| Doki, K | 1 |
| Neuhoff, S | 1 |
| Rostami-Hodjegan, A | 1 |
| Homma, M | 1 |
| Zhang, J | 1 |
| Cao, H | 1 |
| Zhang, Y | 2 |
| Ma, J | 1 |
| Wang, J | 1 |
| Gao, Y | 1 |
| Zhang, X | 1 |
| Zhang, F | 1 |
| Chu, L | 1 |
| Akindele, AJ | 1 |
| Adeneye, AA | 1 |
| Olatoye, F | 1 |
| Benebo, AS | 1 |
| Zou, Z | 1 |
| Xu, FY | 1 |
| Wang, L | 1 |
| An, MM | 1 |
| Zhang, H | 1 |
| Shi, XY | 1 |
| Ali, BH | 1 |
| Al-Qarawi, AA | 1 |
| Mousa, HM | 1 |
| Muñoz Díaz, AB | 1 |
| Aguilar, P | 1 |
| Almquist, T | 1 |
| Forslund, L | 1 |
| Rehnqvist, N | 1 |
| Hjemdahl, P | 1 |
| Kazierad, DJ | 1 |
| Wojcik, GJ | 1 |
| Nix, DE | 1 |
| Goldfarb, AL | 1 |
| Schentag, JJ | 1 |
| Torralbo, A | 1 |
| Trobo, JI | 1 |
| Borque, M | 1 |
| Herrero, JA | 1 |
| Velasco, E | 1 |
| Marcello, M | 1 |
| González-Mate, A | 1 |
| Barrientos, A | 1 |
| Semama, D | 1 |
| Heumann, C | 1 |
| Guignard, JP | 1 |
| Ar'Rajab, A | 1 |
| Dawidson, IJ | 1 |
| Harris, RB | 1 |
| Mileski, WJ | 1 |
| Sentementes, JT | 1 |
| Cohen, EP | 1 |
| Moulder, JE | 1 |
| Fish, BL | 1 |
| Hill, P | 1 |
| Shaikh, MG | 1 |
| Heys, SD | 1 |
| Brown, PA | 1 |
| Whiting, PH | 1 |
| Weinschelbaum-Jairala, S | 1 |
| Ochoa, JE | 1 |
| Elías, MM | 1 |
| Yaman, O | 1 |
| Sarica, K | 1 |
| Ozer, G | 1 |
| Soygür, T | 1 |
| Kutsal, O | 1 |
| Yaman, LS | 1 |
| Göŭş, O | 1 |
| Chan, C | 1 |
| Maurer, J | 1 |
| Cardella, C | 1 |
| Cattran, D | 1 |
| Pei, Y | 1 |
| Lermioglu, F | 1 |
| Bernard, A | 1 |
| Perez de la Cruz, MJ | 1 |
| Cadórniga, R | 1 |
| Ochoa, MC | 1 |
| Albarran, I | 1 |
| Herrero-Vanrell, R | 1 |
| Pastoriza, P | 1 |
| Hemmelder, MH | 1 |
| de Zeeuw, D | 1 |
| de Jong, PE | 1 |
| Jan, CR | 1 |
| Chen, WC | 1 |
| Wu, SN | 1 |
| Tseng, CJ | 1 |
| Hanada, K | 1 |
| Odaka, K | 1 |
| Kudo, A | 1 |
| Ogata, H | 1 |
| Wagner, H | 1 |
| Fritzsche, R | 1 |
| Schmidt, EH | 1 |
| Salducci, MD | 1 |
| Chauvet-Monges, AM | 1 |
| Berland, Y | 1 |
| Dussol, B | 1 |
| Elsen, R | 1 |
| Crevat, A | 1 |
| Farag, MM | 1 |
| Kandil, M | 1 |
| Fadali, GA | 1 |
| Ohyama, A | 3 |
| Tsujino, T | 3 |
| Kumata, N | 1 |
| Kim, T | 3 |
| Yoshimura, R | 3 |
| Nakatani, T | 3 |
| Kusunose, E | 2 |
| Kishimoto, T | 3 |
| Maekawa, M | 2 |
| Sakamoto, W | 2 |
| Maekawa, T | 2 |
| Kawashima, H | 1 |
| Wilson, PD | 1 |
| Hartz, PA | 1 |
| Lenz, T | 1 |
| Müller, FB | 1 |
| Sotelo, JE | 1 |
| Laragh, JH | 1 |
| August, P | 1 |
| L'Azou, B | 1 |
| Lakhdar, B | 1 |
| Potaux, L | 1 |
| Aparicio, M | 1 |
| Cambar, J | 1 |
| Niemczyk, S | 1 |
| Ludwicka, A | 1 |
| Groniowski, M | 1 |
| Lewandowski, Z | 1 |
| Hasse, Z | 1 |
| Wardyn, KA | 1 |
| Dawidson, I | 1 |
| Rooth, P | 1 |
| Hall, TJ | 1 |
| Heckel, C | 1 |
| Browning, MC | 1 |
| Shub, C | 1 |
| Vlietstra, RE | 1 |
| McGoon, MD | 1 |
| Eiskjaer, H | 1 |
| Pedersen, EB | 1 |
| Rasmussen, LM | 1 |
| Jespersen, B | 1 |
| Watson, AJ | 1 |
| Gimenez, LF | 1 |
| Klassen, DK | 1 |
| Stout, RL | 1 |
| Whelton, A | 1 |
| Boero, R | 1 |
| Quarello, F | 1 |
| Guarena, C | 1 |
| Piccoli, G | 1 |
| Kuhlmann, J | 1 |
3 reviews available for verapamil and Kidney Diseases
| Article | Year |
|---|---|
Antihypertensive and renoprotective effects of trandolapril/verapamil combination: a meta-analysis of randomized controlled trials.
Topics: Albuminuria; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hypertension; Indol | 2011 |
Improvement of cadaver renal transplantation outcomes with verapamil: a review.
Topics: Administration, Oral; Blood Pressure; Cyclosporins; Drug Therapy, Combination; Glomerular Filtration | 1991 |
Selection of optimal drug therapy for the patient with angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Blood Pressure; Calcium Channel | 1985 |
5 trials available for verapamil and Kidney Diseases
| Article | Year |
|---|---|
Prognostic implications of renal dysfunction in patients with stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Calcium Channel Blockers; Cardiovascular Disease | 2006 |
A randomized controlled trial of verapamil on cyclosporine nephrotoxicity in heart and lung transplant recipients.
Topics: Adult; Costs and Cost Analysis; Cyclosporine; Female; Glomerular Filtration Rate; Heart-Lung Transpl | 1997 |
Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Cross-Ove | 1999 |
Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium; C | 2002 |
Effects of verapamil, diltiazem, and nifedipine on plasma levels and renal excretion of digitoxin.
Topics: Aged; Benzazepines; Clinical Trials as Topic; Digitoxin; Diltiazem; Drug Interactions; Drug Therapy, | 1985 |
35 other studies available for verapamil and Kidney Diseases
| Article | Year |
|---|---|
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological | 2010 |
Molecular basis of the counteraction by calcium channel blockers of cyclosporine nephrotoxicity.
Topics: Animals; Biomarkers; Blood Urea Nitrogen; Calcium Channel Blockers; Collagen Type IV; Creatinine; Cy | 2018 |
Nephroprotective effect of cilostazol and verapamil against thioacetamide-induced toxicity in rats may involve Nrf2/HO-1/NQO-1 signaling pathway.
Topics: Animals; Antioxidants; Cilostazol; Cytoprotection; Disease Models, Animal; Heme Oxygenase (Decyclizi | 2019 |
Assessing Potential Drug-Drug Interactions Between Dabigatran Etexilate and a P-Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Dabigatran; Drug Dosage Calculations; Drug | 2019 |
Nephroprotective effect of calcium channel blockers against toxicity of lead exposure in mice.
Topics: Animals; Apoptosis; Blood Urea Nitrogen; Body Weight; Calcium Channel Blockers; Creatinine; Cytoprot | 2013 |
Protective effect of selected calcium channel blockers and prednisolone, a phospholipase-A2 inhibitor, against gentamicin and carbon tetrachloride-induced nephrotoxicity.
Topics: Animals; Antioxidants; Biomarkers; Calcium Channel Blockers; Carbon Tetrachloride; Cytoprotection; D | 2014 |
The effect of calcium load and the calcium channel blocker verapamil on gentamicin nephrotoxicity in rats.
Topics: Animals; Anti-Bacterial Agents; Calcium; Calcium Channel Blockers; Creatinine; Dose-Response Relatio | 2002 |
[Idiopathic membranous nephropathy associated with anti-calcineurin toxicity. Prognosis and other immunosuppressive treatments].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcineurin Inhibitors; Ca | 2004 |
The effect of verapamil on the nephrotoxic potential of gentamicin as measured by urinary enzyme excretion in healthy volunteers.
Topics: Adolescent; Adult; CD13 Antigens; Delayed-Action Preparations; Drug Administration Schedule; Gentami | 1995 |
Alterations in renal endothelin production in rats with reduced renal mass.
Topics: Animals; Enalapril; Endothelins; Erythropoietin; Hypertension, Renal; Kidney; Kidney Diseases; Male; | 1995 |
Protection from hypoxemic renal dysfunction by verapamil and manganese in the rabbit.
Topics: Animals; Calcium; Hypoxia; Kidney; Kidney Diseases; Male; Manganese; Rabbits; Verapamil | 1995 |
Deleterious effect of cyclosporins on the ischemic kidney in the rat and the protection by the calcium antagonist verapamil.
Topics: Animals; Creatinine; Cyclosporine; Cyclosporins; Ischemia; Kidney; Kidney Diseases; Male; Nephrectom | 1994 |
Prophylaxis of experimental bone marrow transplant nephropathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Bone Mar | 1994 |
Chronic cyclosporin A (CsA) nephrotoxicity in the rat: the effect of calcium blockade with verapamil.
Topics: Animals; Blood Glucose; Body Weight; Cyclosporine; Kidney; Kidney Diseases; Male; Rats; Rats, Spragu | 1993 |
Influence of trifluoperazine and verapamil on the isolated perfused rat kidney.
Topics: Animals; Antipsychotic Agents; Biomarkers; Calcium Channel Blockers; In Vitro Techniques; Kidney; Ki | 1996 |
Protective effect of verapamil on renal tissue during shockwave application in rabbit model.
Topics: Animals; Calcium Channel Blockers; Disease Models, Animal; Drug Evaluation, Preclinical; Kidney Dise | 1996 |
Effect of calmodulin-inhibitors and verapamil on the nephrotoxicity of cadmium in rat.
Topics: Animals; Cadmium Chloride; Calcium Channel Blockers; Calmodulin; Chlorpromazine; Dopamine Antagonist | 1998 |
Chronopharmacokinetics and calcium in the prevention of gentamicin-induced nephrotoxicity in rabbits.
Topics: Animals; Calcium Channel Blockers; Calcium Chloride; Drug Interactions; Gentamicins; Injections, Int | 1998 |
Nifedipine, verapamil and diltiazem block shock-wave-induced rises in cytosolic calcium in MDCK cells.
Topics: Adenosine Triphosphate; Animals; Aspartate Aminotransferases; Bradykinin; Calcium; Calcium Channel B | 1998 |
Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats.
Topics: Animals; Anti-Arrhythmia Agents; Antineoplastic Agents; Area Under Curve; Biotransformation; Blood U | 1999 |
[Partusisten as a possible cause for renal colics (author's transl)].
Topics: Colic; Drug Therapy, Combination; Ethanolamines; Female; Fenoterol; Humans; Kidney Diseases; Muscle, | 1976 |
The restoration of ATP synthesis may explain the protective effect of calcium antagonists against cyclosporine A nephrotoxicity.
Topics: Adenosine Triphosphate; Animals; Calcium; Calcium Channels; Cyclosporine; Kidney; Kidney Diseases; M | 1992 |
Verapamil increases the nephrotoxic potential of gentamicin in rats.
Topics: Animals; Blood Urea Nitrogen; Body Weight; Creatinine; Drug Interactions; Gentamicins; Injections, I | 1992 |
Correlation of cyclosporine-induced nephropathy with renal microsomal cytochrome P-450: the preventive effect of verapamil.
Topics: Animals; Cyclosporine; Cytochrome P-450 Enzyme System; Kidney; Kidney Diseases; Male; Microsomes; Ra | 1992 |
Effect of ciclosporin on cardiac output and regional blood flow in rats: ciclosporin-induced nephropathy and its prevention with calcium channel blocker.
Topics: Animals; Cardiac Output; Cyclosporine; Hemodynamics; Ischemia; Kidney; Kidney Diseases; Male; Rats; | 1992 |
[Effects of verapamil on cyclosporine. A (CsA)-induced nephropathy in ischemic kidney model in rats: changes in systemic hemodynamics and hepatic and renal microsomal cytochrome P-450].
Topics: Animals; Cyclosporine; Cytochrome P-450 Enzyme System; Disease Models, Animal; Enzyme Induction; Hem | 1991 |
Mechanisms of cyclosporine A toxicity in defined cultures of renal tubule epithelia: a role for cysteine proteases.
Topics: Animals; Calcium; Cell Death; Cells, Cultured; Cyclosporine; Cysteine Endopeptidases; Cysteine Prote | 1991 |
Hemodynamic responses to verapamil monotherapy in patients with renal disease.
Topics: Adult; Aged; Aldosterone; Female; Glomerular Filtration Rate; Hemodynamics; Humans; Kidney; Kidney D | 1991 |
[Effect of verapamil on cyclosporine-induced vasoconstriction in human or murine isolated glomerules].
Topics: Animals; Cyclosporine; Depression, Chemical; Humans; In Vitro Techniques; Kidney; Kidney Diseases; M | 1991 |
[Nephrotoxicity of aminoglycosides. II. Preventive studies with oral administration of verapamil].
Topics: Administration, Oral; Animals; Gentamicins; Kidney Diseases; Male; Rats; Rats, Inbred Strains; Verap | 1991 |
Lack of effect of verapamil and MDL 646, a cytoprotective PGE1 analogue on cyclosporin A nephrotoxicity in vitro.
Topics: Alprostadil; Animals; Anti-Ulcer Agents; Cattle; Cell Division; Cells, Cultured; Cyclosporins; Kidne | 1990 |
Effect of verapamil on cephaloridine nephrotoxicity in the rabbit.
Topics: Animals; Calcium; Cephaloridine; Female; Kidney Cortex; Kidney Diseases; Kidney Tubular Necrosis, Ac | 1990 |
Sustained release verapamil in renal hypertension.
Topics: Adult; Aldosterone; Angiotensin II; Arginine Vasopressin; Atrial Natriuretic Factor; Blood Pressure; | 1988 |
Calcium channel blockade in experimental aminoglycoside nephrotoxicity.
Topics: Animals; Calcium; Calcium Channel Blockers; Creatinine; Gentamicins; Kidney; Kidney Diseases; Male; | 1987 |
Verapamil in arterial hypertension with renal disease.
Topics: Adult; Female; Humans; Hypertension, Renal; Kidney Diseases; Male; Middle Aged; Verapamil | 1986 |